PALI
Palisade Bio, Inc.
Biotechnology
Market Cap$111M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PALI vs VNDA
Revenue, margins, valuation, and 5-year total return — side by side.
VNDA
Vanda Pharmaceuticals Inc.
Biotechnology
Market Cap$378M
5Y Perf.-45.5%
PALI vs VNDA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PALI | VNDA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $111M | $378M |
| Revenue (TTM) | $0.00 | $218M |
| Net Income (TTM) | $-17M | $-240M |
| Gross Margin | — | 71.1% |
| Operating Margin | — | -73.6% |
| Total Debt | $71K | $13M |
| Cash & Equiv. | $133M | $85M |
PALI vs VNDA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PALI
VNDA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Palisade Bio, Inc. (PALI) | 100 | 0.0 | -100.0% |
| Vanda Pharmaceutica… (VNDA) | 100 | 54.5 | -45.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PALI vs VNDA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PALI leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Vanda Pharmaceuticals Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
PALI
Palisade Bio, Inc.
The Growth Play
PALI carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- EPS growth 97.1%
- Lower volatility, beta 1.44, Low D/E 0.1%, current ratio 28.95x
- 16.7% revenue growth vs VNDA's 8.7%
Best for: growth exposure and sleep-well-at-night
VNDA
Vanda Pharmaceuticals Inc.
The Income Pick
VNDA is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.04
- -26.8% 10Y total return vs PALI's -100.0%
- Beta 1.04, current ratio 2.39x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PALI | 16.7% revenue growth vs VNDA's 8.7% |
| Quality / Margins | PALI | -0.0% margin vs VNDA's -110.0% |
| Stability / Safety | VNDA | Beta 1.04 vs PALI's 1.44 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PALI | +161.8% vs VNDA's +45.9% |
| Efficiency (ROA) | PALI | -43.0% ROA vs VNDA's -44.6% |
PALI vs VNDA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
PALI vs VNDA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPALILAGGINGVNDA
VNDAVanda Pharmaceuticals…
1leads
PALIPalisade Bio, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs VNDAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PALI1/1
Valuation MetricsMultiples, price ratios, and targets
PALI2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PALI7/7
Total Returns1Y, 3Y, 5Y total returns with dividends
VNDA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PALI leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
VNDA and PALI operate at a comparable scale, with $218M and $0 in trailing revenue.
| Metric | PALIPalisade Bio, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $218M |
| EBITDAEarnings before interest/tax | -$18M | -$150M |
| Net IncomeAfter-tax profit | -$17M | -$240M |
| Free Cash FlowCash after capex | -$11M | -$127M |
| Gross MarginGross profit ÷ Revenue | — | +71.1% |
| Operating MarginEBIT ÷ Revenue | — | -73.6% |
| Net MarginNet income ÷ Revenue | — | -110.0% |
| FCF MarginFCF ÷ Revenue | — | -58.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +3.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +85.7% | -64.0% |
PALI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
PALI leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | PALIPalisade Bio, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $111M | $378M |
| Enterprise ValueMkt cap + debt − cash | -$23M | $305M |
| Trailing P/EPrice ÷ TTM EPS | -6.63x | -1.71x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.75x |
| Price / BookPrice ÷ Book value/share | 0.86x | 1.15x |
| Price / FCFMarket cap ÷ FCF | — | — |
PALI leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
PALI leads this category, winning 7 of 7 comparable metrics.
Profitability & Efficiency
PALI delivers a -47.8% return on equity — every $100 of shareholder capital generates $-48 in annual profit, vs $-61 for VNDA. PALI carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to VNDA's 0.04x. On the Piotroski fundamental quality scale (0–9), PALI scores 4/9 vs VNDA's 2/9, reflecting mixed financial health.
| Metric | PALIPalisade Bio, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -47.8% | -61.4% |
| ROA (TTM)Return on assets | -43.0% | -44.6% |
| ROICReturn on invested capital | — | -32.2% |
| ROCEReturn on capital employed | -26.3% | -33.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.00x | 0.04x |
| Net DebtTotal debt minus cash | -$133M | -$72M |
| Cash & Equiv.Liquid assets | $133M | $85M |
| Total DebtShort + long-term debt | $71,000 | $13M |
| Interest CoverageEBIT ÷ Interest expense | -1805.60x | — |
PALI leads this category, winning 7 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
VNDA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VNDA five years ago would be worth $3,578 today (with dividends reinvested), compared to $4 for PALI. Over the past 12 months, PALI leads with a +161.8% total return vs VNDA's +45.9%. The 3-year compound annual growth rate (CAGR) favors VNDA at -2.7% vs PALI's -56.9% — a key indicator of consistent wealth creation.
| Metric | PALIPalisade Bio, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -20.4% | -22.5% |
| 1-Year ReturnPast 12 months | +161.8% | +45.9% |
| 3-Year ReturnCumulative with dividends | -92.0% | -7.8% |
| 5-Year ReturnCumulative with dividends | -100.0% | -64.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | -26.8% |
| CAGR (3Y)Annualised 3-year return | -56.9% | -2.7% |
VNDA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PALI and VNDA each lead in 1 of 2 comparable metrics.
Risk & Volatility
VNDA is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than PALI's 1.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PALI currently trades 69.7% from its 52-week high vs VNDA's 64.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PALIPalisade Bio, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.44x | 1.04x |
| 52-Week HighHighest price in past year | $2.85 | $9.94 |
| 52-Week LowLowest price in past year | $0.53 | $3.81 |
| % of 52W HighCurrent price vs 52-week peak | +69.7% | +64.3% |
| RSI (14)Momentum oscillator 0–100 | 47.9 | 54.9 |
| Avg Volume (50D)Average daily shares traded | 3.9M | 1.6M |
Evenly matched — PALI and VNDA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PALI as "Buy" and VNDA as "Buy". Consensus price targets imply 121.8% upside for VNDA (target: $14) vs -24.6% for PALI (target: $2).
| Metric | PALIPalisade Bio, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $1.50 | $14.17 |
| # AnalystsCovering analysts | 3 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PALI leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). VNDA leads in 1 (Total Returns). 1 tied.
Best OverallPalisade Bio, Inc. (PALI)Leads 3 of 6 categories
Loading custom metrics...
PALI vs VNDA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PALI or VNDA a better buy right now?
Analysts rate Palisade Bio, Inc.
(PALI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PALI or VNDA?
Over the past 5 years, Vanda Pharmaceuticals Inc.
(VNDA) delivered a total return of -64. 2%, compared to -100. 0% for Palisade Bio, Inc. (PALI). Over 10 years, the gap is even starker: VNDA returned -26. 8% versus PALI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PALI or VNDA?
By beta (market sensitivity over 5 years), Vanda Pharmaceuticals Inc.
(VNDA) is the lower-risk stock at 1. 04β versus Palisade Bio, Inc. 's 1. 44β — meaning PALI is approximately 39% more volatile than VNDA relative to the S&P 500. On balance sheet safety, Palisade Bio, Inc. (PALI) carries a lower debt/equity ratio of 0% versus 4% for Vanda Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — PALI or VNDA?
On earnings-per-share growth, the picture is similar: Palisade Bio, Inc.
grew EPS 97. 1% year-over-year, compared to -1068. 8% for Vanda Pharmaceuticals Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PALI or VNDA?
Palisade Bio, Inc.
(PALI) is the more profitable company, earning 0. 0% net margin versus -102. 0% for Vanda Pharmaceuticals Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PALI leads at 0. 0% versus -70. 0% for VNDA. At the gross margin level — before operating expenses — VNDA leads at 94. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PALI or VNDA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PALI or VNDA better for a retirement portfolio?
For long-horizon retirement investors, Vanda Pharmaceuticals Inc.
(VNDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04)). Both have compounded well over 10 years (VNDA: -26. 8%, PALI: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PALI and VNDA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.